Innovation

A Physiological Assay for Antipsychotic Action

The Research Foundation of the State University of New York
posted on 07/16/2009

A physiological assay for purposes of psychotic disorders like schizophrenia where patients experience confusion, dellusion, hallucination, and general disorganization of thought.

Advantages

There is no existing physiological model for psychosis and thus no physiological assays for antipsychotic efficacy. The assay can be performed in one afternoon. The assay is reliable, relatively easy to induce and record. It is specific and one knows where to look and what brain changes are important for the antipsychotic action to counter.

Innovation Details
 

Detailed Description

A large percentage of the international population is affected with some sort of psychotic disorder if left undiagnosed and untreated could result in injury to the person with the disorder and/or to people associated and/or close to the person with the disorder. Diagnosis of a psychological disorder can often take time to properly diagnose with only a handful of approved drugs available to treat such disorders once they are diagnosed. Also, conventional methods of determining the anti-psychotic properties of a candidate agent are often times consuming and costly. Very few new candidates that are totally different from existing drugs ever make it to the discovery stage because of a lack of money when this stage is reached. In 2005 a NIH-funded study found treatments with contemporary antipsychotics were no more effective than with drugs that were introduced up to 40 years ago. In the brain, cognitive representations of external stimuli and thought (

File Number: R1548-100 

Other Information: Principal Investigator: Andr


IP Protection

Patent Number(s): 60/798,617

License Online

This innovation currently is not available for online licensing. Please contact Dr. Yalcintas at The Research Foundation of the State University of New York for more information.

Request more info via email request more info
People

Case Manager:

Dr. Yalcintas Dr. Yalcintas

Innovations (31)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

8,805 members 16,684 innovations 159 organizations

Browse

Patrick Jones, Ph.D. Director, Technology Transfer - University of Arizona

"The iBridge Network nicely embodies the ideals of a well-designed, non-profit mechanism for aggregating, searching, and disseminating innovations from multiple research institutions."  read more...